Dergiler / Anatolian Bryology / 2026 / Cilt: 12 Sayı: 2

Diyabet ve obezite için potansiyel bir alfa-glukozidaz inhibitörü olarak Marchantin C’nin moleküler docking ve ADMET profilleme ile in silico değerlendirmesi

In silico evaluation of Marchantin C as a potential alpha-glucosidase inhibitor for diabetes and obesity with molecular docking and ADMET profiling

Ergin Murat Altuner(Kastamonu University, Faculty of Science)0000-0001-5351-8071
Sayfa
76–87
Yayın Tarihi
2026-11-13
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

AutoDock Vina aracılığıyla gerçekleştirilen moleküler docking simülasyonları, Marchantin C'nin -8.6 kcal/mol ile olağanüstü bir bağlanma afinitesine sahip olduğunu ve klinik referans ilaçlar olan akarboz (-6.3 kcal/mol) ile miglitolün (-5.0 kcal/mol) performansını anlamlı ölçüde geride bıraktığını ortaya koymuştur.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Obezite ve diyabet gibi metabolik bozukluklar yeni ve etkili enzim inhibitörlerinin keşfini zorunlu kılmaktadır.
📊
Temel Bulgular & Veri:Bu çalışmada Marchantin C'nin, insan bağırsak α-glukozidazına karşı inhibitör potansiyeli, entegre in silico yaklaşımlar kullanılarak değerlendirilmiştir.
💡
Sonuç & Katkı:AutoDock Vina aracılığıyla gerçekleştirilen moleküler docking simülasyonları, Marchantin C'nin -8.6 kcal/mol ile olağanüstü bir bağlanma afinitesine sahip olduğunu ve klinik referans ilaçlar olan akarboz (-6.3 kcal/mol) ile miglitolün (-5.0 kcal/mol) performansını anlamlı ölçüde geride bıraktığını ortaya koymuştur.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Marchantiophyta · Ciğerotları · Marchantin C

Özet

Obezite ve diyabet gibi metabolik bozukluklar yeni ve etkili enzim inhibitörlerinin keşfini zorunlu kılmaktadır. Alfa-glukozidaz enzimi, yemek sonrası (postprandiyal) hipergliseminin kontrol altına alınmasında terapötik bir hedeftir. Bu çalışmada Marchantin C'nin, insan bağırsak α-glukozidazına karşı inhibitör potansiyeli, entegre in silico yaklaşımlar kullanılarak değerlendirilmiştir. AutoDock Vina aracılığıyla gerçekleştirilen moleküler docking simülasyonları, Marchantin C'nin -8.6 kcal/mol ile olağanüstü bir bağlanma afinitesine sahip olduğunu ve klinik referans ilaçlar olan akarboz (-6.3 kcal/mol) ile miglitolün (-5.0 kcal/mol) performansını anlamlı ölçüde geride bıraktığını ortaya koymuştur. Özellikle, Marchantin C'nin bağlanma enerjisi, akarbozun orijinal (native-fixed) pozundan (-7.8 kcal/mol) dahi daha üstün bulunmuş; bu durum molekülün katalitik cep içindeki yüksek termodinamik kararlılığını doğrulamıştır. Etkileşim analizi, Marchantin C'nin enzimin katalitik merkezini etkili bir şekilde hedeflediğini ve Trp406 ile yapılan Pi-Pi istiflenmesiyle (stacking) desteklenen, Asp203 ve Thr205 kalıntılarıyla kritik bağlar kurduğunu göstermiştir. Ayrıca, SwissADME aracılığıyla yapılan ADMET ve farmakokinetik profilleme, Marchantin C'nin yüksek gastrointestinal emilim sergilediğini ve Lipinski'nin Beşli Kuralı'na uyum sağlayan elverişli bir ilaç benzerliği profiline sahip olduğunu göstermiştir. BOILED-Egg ve biyoyararlanım radar grafikleri üzerinden yapılan görselleştirmeler, molekülün oral yoldan aktif bir ajan olma potansiyelini daha da desteklemiştir. Bu bulgular, Marchantin C'nin tip 2 diyabet ve obezite yönetimi için umut verici bir doğal öncü bileşik olduğuna dair güçlü hesaplamalı kanıtlar sunmakta ve ileri düzey in vivo araştırmaların gerekliliğine işaret etmektedir.

Abstract

Metabolic disorders, such as obesity and diabetes, necessitate the discovery of novel and effective enzyme inhibitors. Alpha-glucosidase is a therapeutic target for controlling postprandial hyperglycemia. The inhibition potential of Marchantin C, was evaluated against human intestinal α-glucosidase using integrated in silico approaches in this study. Molecular docking simulations performed via AutoDock Vina revealed that Marchantin C possesses an exceptional binding affinity of -8.6 kcal/mol, significantly outperforming the clinical reference drugs acarbose (-6.3 kcal/mol) and miglitol (-5.0 kcal/mol). Notably, the binding energy of Marchantin C was also superior to the native-fixed pose of acarbose (-7.8 kcal/mol), confirming its high thermodynamic stability within the catalytic pocket. Interaction analysis demonstrated that Marchantin C effectively targets the enzyme's catalytic centre, forming crucial bonds with residues Asp203 and Thr205, supplemented by Pi-Pi stacking with Trp406. Furthermore, ADMET and pharmacokinetic profiling via SwissADME indicated that Marchantin C exhibits high gastrointestinal absorption and a favourable drug-likeness profile, adhering to Lipinski's Rule of Five. Visualisation through BOILED-Egg and bioavailability radar plots further supported its potential as an orally active agent. These findings provide strong computational evidence that Marchantin C is a promising natural lead compound for managing obesity and type 2 diabetes, warranting further in vivo investigations.

🔖

Bu Makaleye Atıf Yap

Altuner, E. M. (2026). Diyabet ve obezite için potansiyel bir alfa-glukozidaz inhibitörü olarak Marchantin C’nin moleküler docking ve ADMET profilleme ile in silico değerlendirmesi. Anatolian Bryology, Cilt: 12 Sayı: 2, 76–87. https://doi.org/10.26672/anatolianbryology.1982646

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (41)

  1. Abdulhaniff P. Sakayanathan P. Loganathan C. Iruthayaraj A. Thiyagarajan R. Thayumanavan P. 2024. Mammalian maltase-glucoamylase and sucrase-isomaltase inhibitory effects of Artocarpus heterophyllus: An in vitro and in silico approach. Computational Biology and Chemistry. 110, 108052.
  2. Altuner E.M. 2021. In silico proofs for phloridzin, naringenin, and cinnamic acid as alpha-amylase activators, which is important in industrial microbiology or biochemical engineering. Commun. Fac. Sci. Univ. Ank. Series C. 30:2, 134-147.
  3. Altuner E.M. 2022. In silico proof of the effect of quercetin and umbelliferone as alpha-amylase inhibitors, which can be used in the treatment of diabetes. Kastamonu University Journal of Forestry Faculty. 22:3, 202-216.
  4. Asakawa Y. 1982. Chemical constituents of the Hepaticae. Progress in the Chemistry of Organic Natural Products, vol. 42, Herz W. Grisebach H. Kirby G.W. Editor(s). Springer, Vienna. pp. 1-285.
  5. Asakawa Y. 1990. Terpenoids and aromatic compounds with pharmacological activity from bryophytes. Bryophytes: Their chemistry and chemical taxonomy, Zinsmeister H.D. Mues R. Editor(s). Clarendon Press, Oxford, UK. pp.369-410.
  6. Asakawa Y. 1995. Chemical constituents of the bryophytes. Progress in the Chemistry of Organic Natural Products, vol. 65. Herz W. Kirby W.B. Moore R.E. Steglich W. Tamm C. Editor(s). Springer, Vienna. pp. 1-618.
  7. Asakawa Y. 2008. Liverworts-potential source of medicinal compounds. Current pharmaceutical design. 14:29, 3067-3088.
  8. Asakawa Y. 2017. Polyphenols in bryophytes: structures, biological activities, and bio-and total syntheses. Recent Advances in Polyphenol Research. Yoshida K. Cheynier V. Quideau S. Editor(s). Wiley Blackwell, Chichester, UK. pp.36-66.
  9. Asakawa Y. Hashimoto T. Takikawa K. Tori M. Ogawa S. 1991. Prenyl bibenzyls from the liverworts Radula perrottetii and Radula complanata. Phytochemistry. 30:1, 235-251.
  10. Asakawa Y. Ludwiczuk A. Nagashima F. 2009. Bryophytes: bio-and chemical diversity, bioactivity and chemosystematics. Heterocycles. 77:1, 99-150.
  11. Asakawa Y. Ludwiczuk A. Nagashima F. 2012. Chemical constituents of bryophyta. Chemical Constituents of Bryophytes: Bio-and Chemical Diversity, Biological Activity, and Chemosystematics. 563-605.
  12. Asakawa Y. Ludwiczuk A. Nagashima F. 2013a. Phytochemical and biological studies of bryophytes. Phytochemistry. 91, 52-80.
  13. Asakawa Y. Ludwiczuk A. Nagashima, F. 2013b. Biologically Active Compounds of the Marchantiophyta and Bryophyta. Chemical Constituents of Bryophytes. Columbus A.D.K Linz H.F. Sapporo J.K. Editor(s). Springer, Vienna. pp. 634.
  14. Asakawa Y. Ludwiczuk A. Novakovic M. Bukvicki D. Anchang K.Y. 2021. Bis-bibenzyls, Bibenzyls, and Terpenoids in 33 Genera of the Marchantiophyta (Liverworts): Structures, Synthesis, and Bioactivity. Journal of Natural Products. 85:3, 729-762.
  15. Asakawa Y. Toyota M. Tori M. Hashimoto T. 2000. Chemical structures of macrocyclic bis (bibenzyls) isolated from liverworts (Hepaticae). Spectroscopy. 14:4, 149-175.
  16. Biovia Dassault Systèmes. 2019. Discovery Studio Visualizer v.20.1.0.19295 [Computer software]. San Diego: Dassault Systèmes.
  17. Daina A. Michielin O. Zoete V. 2017. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports. 7:1. 1-13.
  18. Dallakyan S. Olson, A. J. 2014. Small-molecule library screening by docking with PyRx. Chemical biology: methods and protocols. Hempel J.E. Williams C.H. Hong C.C. Editor(s). Springer, New York. pp. 243-250.
  19. Fastanti F.S. Wulansari T.Y.I. 2021. The dynamics of bryophytes species diversity in the lowland ecosystems, cibinong science center-botanical garden. Jurnal Ilmiah Biologi Eksperimen dan Keanekaragaman Hayati. 8:2, 8-17.
  20. Graham L.E. Wilcox L.W. Cook M.E. Gensel P.G. 2004. Resistant tissues of modern marchantioid liverworts resemble enigmatic Early Paleozoic microfossils. Proceedings of the National Academy of Sciences. 101:30, 11025-11029.
  21. Harinantenaina L. Kida S. Asakawa Y. 2007. Phytochemistry of three selected liverworts: Conocephalum conicum, Plagiochila barteri and P. terebrans. Arkivoc. 7, 22-29.
  22. Heinrichs J. Gradstein S.R. Wilson R. Schneider H. 2005. Towards a natural classification of liverworts (Marchantiophyta) based on the chloroplast gene rbcL. Cryptogamie, Bryologie. 26:2, 131-150.
  23. Huang W.J. Wu C.L. Lin C.W. Chi L.L. Chen P.Y. Chiu C.J. Huang C.Y. Chen C.N. 2010. Marchantin A, a cyclic bis (bibenzyl ether), isolated from the liverwort Marchantia emarginata subsp. tosana induces apoptosis in human MCF-7 breast cancer cells. Cancer Letters. 291:1, 108-119.
  24. Iwai Y. Murakami K. Gomi Y. Hashimoto T. Asakawa Y. Okuno Y. Ishikawa T. Hatakeyama D. Echigo N. Kuzuhara T. 2011. Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. PLoS One. 6:5, e19825.
  25. Kenrick P. Crane P.R. 1997. The origin and early evolution of plants on land. Nature. 389:6646, 33-39.
  26. Keserű G.M. Nógrádi M. 1995. The chemistry of macrocyclic bis (bibenzyls). Natural Product Reports. 12:1, 69-75. Leeson P. 2012. Chemical beauty contest. Nature. 481:7382, 455-456.
  27. Ludwiczuk A Asakawa, Y. 2019. Bryophytes as a source of bioactive volatile terpenoids-A review. Food and Chemical Toxicology. 132, 110649.
  28. Panossian A. Gabrielian E. Schwartner C. Wagner H. 1996. Marchantin B from the liverwort Marchantia polymorpha selectively inhibits the biosynthesis of 5-lipoxygenase products and the release of arachidonic acid in Ca (+ 2) ionophore A 23187 stimulated human granulocytes. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. 2:4, 309-311.
  29. Qiu Y.L. Cho Y. Cox J.C. Palmer J.D. 1998. The gain of three mitochondrial introns identifies liverworts as the earliest land plants. Nature. 394:6694, 671-674.
  30. Rahman N. Muhammad I. Khan H. Aschner M. Filosa R. Daglia M. 2019. Molecular docking of isolated alkaloids for possible α-glucosidase inhibition. Biomolecules. 9:10, 544.
  31. Rosenquist K.J. Fox C.S. 2021. Mortality trends in type 2 diabetes. Cowie C.C. Casagrande S.S. Menke A. Cissell M.A. Eberhardt M.S. Meigs J.B. Gregg E.W. Knowler W.C. Barrett-Connor E. Becker D.J. Brancati F.L. Boyko E.J. Herman W.H. Howard B.V. Narayan K.M.V. Rewers M. Fradkin J.E. Editor(s). Bethesda, US. pp. 1-14.
  32. Schwartner C. Bors W. Michel C. Franck U. Müller-Jakic B. Nenninger A. Asakawa Y. Wagner, H. 1995. Effect of marchantins and related compounds on 5-lipoxygenase and cyclooxygenase and their antioxidant properties: a structure activity relationship study. Phytomedicine. 2:2, 113-117.
  33. Schwartner C. Michel C. Stettmaier K. Wagner H. Bors W. 1996. Marchantins and related polyphenols from liverwort: physico-chemical studies of their radical-scavenging properties. Free Radical Biology and Medicine. 20:2, 237-244.
  34. Shen J. Li G. Liu Q. He Q. Gu J. Shi Y. Lou H. 2010. Marchantin C: a potential anti-invasion agent in glioma cells. Cancer Biology & Therapy. 9:1, 33-39.
  35. Shi Y.Q. Liao Y.X. Qu X.J. Yuan H.Q. Li S. Qu J.B. Lou H.X. 2008. Marchantin C, a macrocyclic bisbibenzyl, induces apoptosis of human glioma A172 cells. Cancer Letters. 262:2, 173-182.
  36. Sim L. Quezada-Calvillo R. Sterchi E.E. Nichols B.L. Rose D.R. 2008. Human intestinal maltase–glucoamylase: crystal structure of the N-terminal catalytic subunit and basis of inhibition and substrate specificity. Journal of Molecular Biology. 375:3, 782-792.
  37. Trott O. Olson A.J. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry. 31:2, 455-461.
  38. Tundis R. Loizzo M.R. Menichini F. 2010. Natural products as α-amylase and α-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. Mini Reviews in Medicinal Chemistry. 10:4, 315-331.
  39. URL1. Hanwell M.D. Hutchison G.R. 2026. Avogadro2. Website: https://github.com/openchemistry/avogadrolibs/releases/tag/2.0.0 [Accessed: 28 June 2026].
  40. URL2. Sim L. Rose D.R. 2026. Crystral Structure of the N-terminal Subunit of Human Maltase-Glucoamylase in Complex with Acarbose. Website: https://files.rcsb.org/validation/view/2qmj_full_validation.pdf [Accessed: 28 June 2026].
  41. Wellman C.H. Osterloff P.L. Mohiuddin U. 2003. Fragments of the earliest land plants. Nature. 425:6955, 282-285.